BioSpace News Archive

PostEra , a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by developing a platform technology based on generative chemistry. PostEra and Pfizer Inc. e

CEL-SCI Corporation (NYSE American: CVM) announced today that the Phase 3 study is in the final stage of review which involves statistical analysis of all study data. Data lock has already been completed. Since the required number of events to allow statistical analysis of CEL-SCI’s Phase 3 study in head and neck cancer was reached earlier thi

MobileSmith Health, a leader in the digital health and mobile development sector that is reshaping traditional healthcare, announced the appointment of David Wardlaw as chief revenue officer.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRUM) today announced that it will host its inaugural Virtual Investor Day on December 9, 2020 from 11:00 a.m. – 1:30 p.m. ET. The webcast will include an overview of Mirum’s strategy and commercial plans for its lead investigational medication, maralixibat, as well as development progress for maralixibat and volixibat, both of which are being evaluated for the treatment of p

LGC Maine Standards¹ announces the release of VALIDATE ® Tumor Markers to meet the linearity and calibration verification needs of clinical laboratories running the Abbott Architect and Abbott Alinity platforms. The product (Order No. 407AB), which includes analytes CEA, CA 125, CA 15-3, and CA 19-9 , is formulated in

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021. Data were presented at the virtual 62nd American Society of Hematology (AS

Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7 % of patients treated with pegcetacoplan compared to 5.1% of eculizumab -treated patients achieved a good , major, or complete hematologic response based on published classifications

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two triple therapy combination data

Economic activity in the hospital subsector grew in November for the sixth consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.